PRODUCT MONOGRAPH PREPIDIL (dinoprostone gel) 0.5 mg/2.5
... by defecation of the animals within 15 minutes. Using fecal weight as an end-point, concentrations of dinoprostone as low as 0.8 μg/kg can be detected. Repeated dosage with this compound under the test conditions described above causes frank diarrhea in the test animals. ...
... by defecation of the animals within 15 minutes. Using fecal weight as an end-point, concentrations of dinoprostone as low as 0.8 μg/kg can be detected. Repeated dosage with this compound under the test conditions described above causes frank diarrhea in the test animals. ...
In Vitro-In Vivo Correlation (IVIVC) and Determining
... mostly conducted in vessel-based apparatuses, commonly known as the paddle and basket apparatuses [1] to demonstrate appropriate release characteristics of API. The core components of these apparatuses are a vessel and a stirrer. Such tests are commonly interchangeably referred to as in vitro dissol ...
... mostly conducted in vessel-based apparatuses, commonly known as the paddle and basket apparatuses [1] to demonstrate appropriate release characteristics of API. The core components of these apparatuses are a vessel and a stirrer. Such tests are commonly interchangeably referred to as in vitro dissol ...
as diaspartate - Therapeutic Goods Administration
... SIGNIFOR is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative. ...
... SIGNIFOR is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative. ...
Experimental Designs for Drug Combination Studies
... The interest in drug combinations is growing rapidly due to the opportunities they create to increase the therapeutic effect and to reduce the frequency or magnitude of undesirable side effects when single drugs fail to deliver satisfactory results. Considerable effort in studying the mechanisms lea ...
... The interest in drug combinations is growing rapidly due to the opportunities they create to increase the therapeutic effect and to reduce the frequency or magnitude of undesirable side effects when single drugs fail to deliver satisfactory results. Considerable effort in studying the mechanisms lea ...
Design fabrication and characterization of controlled
... release forms lead to maximum plasma levels immediately after administration and to a very low plasma level at the time of the next dose, resulting in great differences in peak and through plasma levels at steady state.[3] Trimtazidine di hydrochloride is regarded as a safe drug in the long term tre ...
... release forms lead to maximum plasma levels immediately after administration and to a very low plasma level at the time of the next dose, resulting in great differences in peak and through plasma levels at steady state.[3] Trimtazidine di hydrochloride is regarded as a safe drug in the long term tre ...
1. circumstances when shared care is appropriate
... Educate patient about all aspects of treatment including potential adverse effects and monitoring requirements. Provide Arthritis Research Campaign (ARC) patient information sheet on Leflunomide. Issue / explain shared care monitoring card. Starting treatment: Prescribe leflunomide for at le ...
... Educate patient about all aspects of treatment including potential adverse effects and monitoring requirements. Provide Arthritis Research Campaign (ARC) patient information sheet on Leflunomide. Issue / explain shared care monitoring card. Starting treatment: Prescribe leflunomide for at le ...
stromectol
... Streptomyces avermitilis. It binds selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarisation of the nerve or muscle cell, r ...
... Streptomyces avermitilis. It binds selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarisation of the nerve or muscle cell, r ...
Product Monograph - AstraZeneca Canada
... Due to lack of relevant experience, treatment with DAXAS should not be initiated or existing treatment with DAXAS should be stopped in patients with severe immunological diseases (e.g. HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy) or patients bei ...
... Due to lack of relevant experience, treatment with DAXAS should not be initiated or existing treatment with DAXAS should be stopped in patients with severe immunological diseases (e.g. HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy) or patients bei ...
Cp min = 8mg /l
... and 10% ethanol and adjusted to a pH of 12 with the addition of sodium hydroxide to maintain solubility. -Phenytoin administered intravenously at a rate greater than 50 mg/min may cause hypotension and arrhythmias. These complications are believed to be secondary to the diluent, propylene glycol(whi ...
... and 10% ethanol and adjusted to a pH of 12 with the addition of sodium hydroxide to maintain solubility. -Phenytoin administered intravenously at a rate greater than 50 mg/min may cause hypotension and arrhythmias. These complications are believed to be secondary to the diluent, propylene glycol(whi ...
Datasheet Methylprednisolone Sodium Succinate
... In other indications, initial dosage will vary from 10 to 500 milligrams depending on the clinical problem being treated. Larger doses may be required for short term management of severe, acute conditions. The initial dose, up to 250 milligrams, should be given intravenously over a period of at leas ...
... In other indications, initial dosage will vary from 10 to 500 milligrams depending on the clinical problem being treated. Larger doses may be required for short term management of severe, acute conditions. The initial dose, up to 250 milligrams, should be given intravenously over a period of at leas ...
The Use of Functional Chemical-Protein Associations to Identify
... Based on a the huge number of proteins expressed in the human body [25], this result implies a high probability that a chemical or a drug is functionally associated with more than one gene products. Targeting multiple functionally related proteins endows chemicals with the potential to correct the d ...
... Based on a the huge number of proteins expressed in the human body [25], this result implies a high probability that a chemical or a drug is functionally associated with more than one gene products. Targeting multiple functionally related proteins endows chemicals with the potential to correct the d ...
Dangerous Abbreviations, Symbols and Dose Designations
... Dangerous Abbreviations, Symbols and Dose Designations The abbreviations, symbols, and dose designations found in this table have been reported as being frequently misinterpreted and involved in harmful medication errors. They should NEVER be used when communicating medication information. ...
... Dangerous Abbreviations, Symbols and Dose Designations The abbreviations, symbols, and dose designations found in this table have been reported as being frequently misinterpreted and involved in harmful medication errors. They should NEVER be used when communicating medication information. ...
Severe Dapsone Hypersensitivity Syndrome
... no comparative studies regarding their effectiveness have been performed to date. Since dapsone persists up to 35 days in organs through protein binding and enterohepatic recirculation, slow tapering off the corticosteroid therapy over at least 1 month with close monitoring of organ function is requ ...
... no comparative studies regarding their effectiveness have been performed to date. Since dapsone persists up to 35 days in organs through protein binding and enterohepatic recirculation, slow tapering off the corticosteroid therapy over at least 1 month with close monitoring of organ function is requ ...
Cardiovascular Disease Manual
... Strength to use depends on interval to first craving upon awakening: <30minutes, use 4mg; > 30minutes, use 2mg. Place patch on relatively hairless area between neck and waist. Apply patch to different place each day. See package insert for tips to maximize adhesion. Side Effects: Local skin irritati ...
... Strength to use depends on interval to first craving upon awakening: <30minutes, use 4mg; > 30minutes, use 2mg. Place patch on relatively hairless area between neck and waist. Apply patch to different place each day. See package insert for tips to maximize adhesion. Side Effects: Local skin irritati ...
Jan p. 2 - Epocrates
... when a clinically important DDI was identified. A false negative occurred when a clinically significant interaction was not identified but should have been. A true negative occurred when a clinically unimportant DDI was not identified, and a false positive occurred when a DDI was identified but was ...
... when a clinically important DDI was identified. A false negative occurred when a clinically significant interaction was not identified but should have been. A true negative occurred when a clinically unimportant DDI was not identified, and a false positive occurred when a DDI was identified but was ...
Review the published MAY03-1-BIO manuscript.
... AUC0-24 h for sulindac and each metabolite are provided in Table 2 for both formulations. Plasma concentrationtime curves are illustrated in Fig. 1. Following a short delay of 0.46 h, a mean peak plasma concentration of 3.34Ag/mL for sulindac sulfoxide was achieved 1.90 h after administration of the ...
... AUC0-24 h for sulindac and each metabolite are provided in Table 2 for both formulations. Plasma concentrationtime curves are illustrated in Fig. 1. Following a short delay of 0.46 h, a mean peak plasma concentration of 3.34Ag/mL for sulindac sulfoxide was achieved 1.90 h after administration of the ...
Pr TECFIDERA™ - Biogen Canada
... infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. During the clinical trial, the patient experienced prolonged lymphopenia (lymphocyte counts predominantly <0.5x109/L for 3.5 yea ...
... infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. During the clinical trial, the patient experienced prolonged lymphopenia (lymphocyte counts predominantly <0.5x109/L for 3.5 yea ...
US FDA Drug Approval Strategies for Pharmaceutical Industry
... with 21CFR Sec.312.23 or Sec.312.34. It is also used for patients who do not meet the criteria of an existing study protocol, or if an approved study protocol does not exist. ...
... with 21CFR Sec.312.23 or Sec.312.34. It is also used for patients who do not meet the criteria of an existing study protocol, or if an approved study protocol does not exist. ...
Single-Dose Administration of Bowman
... In this study, the effects of the administration of a single oral dose of BBIC were monitored. The highest dose used in this human trial was 800 CIU/day. This upper limit for human dosing was established from the results of BBIC toxicity testing in dogs. The highest dose of BBIC evaluated in dog tox ...
... In this study, the effects of the administration of a single oral dose of BBIC were monitored. The highest dose used in this human trial was 800 CIU/day. This upper limit for human dosing was established from the results of BBIC toxicity testing in dogs. The highest dose of BBIC evaluated in dog tox ...
PROT Opioid Tolerant Adult Pain
... Q4H PRN, Oral, Dose: 1-2 tablets, PRN for moderate pain. Maximum dose of acetaminophen is 4000 mg from all sources in 24 hours. Q4H PRN, Oral, Dose: 1-2 tablets, PRN for moderate pain. Maximum dose of acetaminophen is 4000 mg from all sources in 24 hours.. Q4H PRN, Oral, Dose: 1-2 tablets, PRN for m ...
... Q4H PRN, Oral, Dose: 1-2 tablets, PRN for moderate pain. Maximum dose of acetaminophen is 4000 mg from all sources in 24 hours. Q4H PRN, Oral, Dose: 1-2 tablets, PRN for moderate pain. Maximum dose of acetaminophen is 4000 mg from all sources in 24 hours.. Q4H PRN, Oral, Dose: 1-2 tablets, PRN for m ...
